Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/14/2013

alatin Technologies, Inc., such as statements about clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates and market potential for product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.  Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

 PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statements of Operations(unaudited)Three Months Ended December 31,Six Months Ended December 31,2012201120122011REVENUES:

$
,555$
,492$
,361$
38,709OPERATING EXPENSES:Research and development

2,445,7702,693,0674,78
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
(Date:8/20/2014)... SAN JOSE, Calif. , Aug. 20, 2014 ... UCSD highlights the transformative collaboration between the school,s ... (IoT).  As part of the Intel® Software Academic ... between computer sciences and the human body.  ... The study exhibits the work of ...
(Date:8/20/2014)... Cranford, NJ (PRWEB) August 20, 2014 ... solutions, announced today that it has expanded its myPROpad™ ... of the EQ-5D-5L, one of the most widely ... for measuring general health status. The EQ-5D is used ... to generate a measure that can be used to ...
(Date:8/19/2014)... 2014 One of the major ... an inadequate vascular supply. Nutrient and gas transport ... is critical for successful regeneration and integration into ... deficiencies in vascularization and promote angiogenesis in a ... scaffold design and architecture, and enhancing scaffolds with ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2EQ-5D™ Assessment Now Available for iPad 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... deCODE genetics,(Nasdaq: DCGN ) today ... laboratory, which processes the company,s deCODEme(TM) personal,genome ... several common,diseases, has been accredited by the ... inspection. The U.S. Centers for Medicare and ...
... to Launch into High Growth Brazilian Market for ... Aesthera announced today the receipt of ANVISA clearance ... platforms in Brazil. ANVISA (Agencia Nacional de ... and regulatory agency charged with clearing all applications ...
... in Groton , Connecticut MORRISVILLE, ... contract manufacturer of APIs, intermediates and Drug Products to the ... pleased to announce the recent award by Pfizer Inc. as ... at Pfizer,s Groton, Connecticut R&D center on May 1, 2009. ...
Cached Biology Technology:deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 2deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 3deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 4Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 2Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 3Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem 2
(Date:8/20/2014)... -  Issue Serious allergic reactions to ... threatening for some children.    What you should ... food allergies and this number may be increasing, especially among ... to have food allergies.  The symptoms of ... to breathing difficulties and loss of consciousness. Symptoms can also ...
(Date:8/20/2014)... outcomes of approximately 3 million infants, a team of ... University of Massachusetts Medical School, have shown that newborn ... implemented across public health newborn screening programs. Data from ... issue of the Journal of the American Medical ... SCID in newborns is higher than previously thought and ...
(Date:8/20/2014)... UK scientists have discovered that acral melanomas the rare ... death are genetically distinct from other more common types ... published in the journal Pigment Cell & Melanoma Research ... the hands, soles of the feet, nail-beds and other hairless ... melanoma, it,s not caused by UV damage from the sun. ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... are urgently needed in resource-limited countries. A ... Microbiology colloquium, "Bringing the Lab to the Patient: ... the challenges inherent in bringing new medical devices ... where they are needed most. Point-of-care diagnostics (POCTs) ...
... helped open a new door of possibility in the high-stakes ... an international team, the scientists including Stanford Woods Institute ... found a way to create future ocean conditions in a ... the device can mimic the composition of the future ocean ...
... world dolomite is quite common. More than 90 percent of ... first described scientifically in the 18th century. But who would ... not fully understood, although geologists are aware of large deposits ... years. The process of recent primary dolomite formation is restricted ...
Cached Biology News:Report addresses challenges in implementing new diagnostic tests where they are needed most 2Stanford researchers help predict the oceans of the future with a mini-lab 2How does dolomite form? 2
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
DL-Dithiothreitol (Clelands Reagent) ,PROTEASE FREE!! ,Molecular Biology Grade ,PRODUCT MUST SHIP NEXT DAY DURING HOT SUMMER MONTHS. ,C 4 H 10 O 2 S 2 ,Molecular Weight: 154.25 ,CAS RN: [27565-...
DTT 50 l...
...
Biology Products: